Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viemed Healthcare (VMD) Current Deferred Revenue (2018 - 2025)

Viemed Healthcare's Current Deferred Revenue history spans 8 years, with the latest figure at $7.5 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 12.34% year-over-year to $7.5 million; the TTM value through Dec 2025 reached $7.5 million, up 12.34%, while the annual FY2025 figure was $7.5 million, 12.34% up from the prior year.
  • Current Deferred Revenue reached $7.5 million in Q4 2025 per VMD's latest filing, down from $7.8 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $7.8 million in Q3 2025 to a low of $3.4 million in Q1 2021.
  • Average Current Deferred Revenue over 5 years is $5.5 million, with a median of $6.0 million recorded in 2023.
  • Peak YoY movement for Current Deferred Revenue: grew 0.82% in 2021, then soared 35.39% in 2023.
  • A 5-year view of Current Deferred Revenue shows it stood at $3.8 million in 2021, then increased by 23.21% to $4.6 million in 2022, then skyrocketed by 34.23% to $6.2 million in 2023, then grew by 7.85% to $6.7 million in 2024, then rose by 12.34% to $7.5 million in 2025.
  • Per Business Quant, the three most recent readings for VMD's Current Deferred Revenue are $7.5 million (Q4 2025), $7.8 million (Q3 2025), and $7.2 million (Q2 2025).